Objective:To systematically evaluate the efficacy and safety of epidermal growth factor receptor tyrosine kinase inhibitor monotherapy(gefitinib or erlotinib)with docetaxel monotherapy in previously treated advanced non-small-cell lung cancer(NSCLC).Methods:Pub Med

Embase

Cochrane library

CNKI

Wan-fang Data and VIP were searched to collect randomized clinical trials(RCTs)comparing EGFR-TKI monotherapy with docetaxel chemotherapy in previously treated advanced NSCLC. The hazard ratio(HR)or odds ratio(OR)

with their corresponding 95% confidence intervals(CI)were pooled using Review manager 5.3.0. Results:Six randomized controlled trials involving 2747patients(EGFR-TKI 1389 patients

docetaxel 1358 patients)were eligible. The pooled HRs showed no significant difference in OS(HR=0.90

95%CI=0.78 to 1.04

Z=1.40

P=0.16). PFS was elongated in docetaxel group than in erlotinib group(HR=1.31

95%CI=1.11 to 1.54

Z=3.24

P=0.001). There was no difference in PFS between docetaxel group and gentitinib group(HR=0.90

95%CI=0.78 to 1.04

Z=1.40

P=0.16). Safety analysis showed that incidence of side effect at grade 3 or 4 was low in EGFR-TKI group;the side effects included neutropeni(RR=0.06

95%CI=0.04 to 0.08)

febrile

neutropenia(RR =0.09

95% CI =0.05 to 0.16)

and nurotoxicity(RR=0.25

995%CI=0.05 to 0.16). The incidence of rash at grade3 or 4 was increased(RR=15.03

95%CI=5.81 to 38.88). Conclusion:Although having similar OS and PFS

EGFR-TKI is safer and better tolerated.